Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment (vol 12, pg 134, 2010)

被引:7
|
作者
Hecker, M.
Goertsches, R. H.
Fatum, C.
Koczan, D.
Thiesen, H-J
Guthke, R.
Zettl, U. K.
机构
来源
PHARMACOGENOMICS JOURNAL | 2012年 / 12卷 / 04期
关键词
D O I
10.1038/tpj.2011.12
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Correction to: The Pharmacogenomics Journal (2012) 12, 134–146; doi:10.1038/tpj.2010.77 Elements were omitted from the Supplementary Information that accompanied the online version of this article. For Supplementary Table 1, the following information should have been included: ‘A list of 121 genes up- or downregulated during first 4 weeks of intramuscular IFN-β-1a treatment.
引用
收藏
页码:360 / 360
页数:1
相关论文
共 50 条
  • [41] Interferon-β 1a Modulates Expression of RAGE but Not S100A12 and Nuclear Factor-κB in Multiple Sclerosis Patients
    Asadikaram, Gholamreza
    Noroozi, Saam
    Meimand, Hossein Ali Ebrahimi
    Sanjari, Mojgan
    Zainodini, Nahid
    Khoramdelazad, Hossein
    Shahrokhi, Nader
    Arababadi, Mohammad Kazemi
    NEUROIMMUNOMODULATION, 2016, 23 (5-6) : 345 - 351
  • [42] Interferon-β1b in Multiple Sclerosis: Effect on Progression of Disability and Clinical Markers of Treatment Response
    Carmona, Olga
    Casado, Virginia
    Moral, Ester
    Alonso-Magdalena, Lucia
    Martinez-Yelamos, Antonio
    Martinez-Yelamos, Sergio
    Martin-Ozaeta, Gisela
    Arbizu, Txomin
    EUROPEAN NEUROLOGY, 2008, 60 (06) : 279 - 284
  • [43] Reduction of IL9 may be an early response marker for interferon β 1a treatment in multiple sclerosis patients
    Kurtuncu, M.
    Tuzun, E.
    Petek-Balci, B.
    Birday, E.
    Coban, A.
    Turkoglu, R.
    Icoz, S.
    Pehlivan, M.
    Ulusoy, C.
    Akman-Demir, G.
    Eraksoy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 450 - 450
  • [44] Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients
    Weinstock-Guttman, Bianca
    Bhasi, Kavitha
    Badgett, Darlene
    Tamano-Blanco, Miriam
    Minhas, Miranda
    Feichter, Joan
    Patrick, Kara
    Munschauer, Frederick
    Bakshi, Rohit
    Ramanathan, Murali
    JOURNAL OF NEUROIMMUNOLOGY, 2008, 205 (1-2) : 113 - 125
  • [45] SAFE AND EFFECTIVE USE OF THE SINGLE-USE INTRAMUSCULAR (IM) INTERFERON BETA-1A (IFNβ-1A) AUTOINJECTOR IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)
    Phillips, J. T.
    Tuccillo, D.
    Liu, S.
    Curnow, K.
    Deykin, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 537 - 537
  • [46] Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis
    Rosjo, Egil
    Myhr, Kjell-Morten
    Loken-Amsrud, Kristin I.
    Bakke, Soren J.
    Beiske, Antonie G.
    Bjerve, Kristian S.
    Hovdal, Harald
    Lilleas, Finn
    Midgard, Rune
    Pedersen, Tom
    Benth, Jurate Saltyte
    Torkildsen, Oivind
    Wergeland, Stig
    Michelsen, Annika E.
    Aukrust, Pal
    Ueland, Thor
    Holmoy, Trygve
    JOURNAL OF NEUROIMMUNOLOGY, 2015, 280 : 21 - 28
  • [47] Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis
    Nicola S. Orefice
    Mireille Alhouayek
    Antonio Carotenuto
    Silvana Montella
    Franscesco Barbato
    Albert Comelli
    Antonio Calignano
    Giulio G. Muccioli
    Giuseppe Orefice
    Neurotherapeutics, 2016, 13 : 428 - 438
  • [48] Treatment of disease progression in relapsing multiple sclerosis with combination therapy of interferon-β-1a (Avonex®) plus pulse steroids, cyclophosphamide, and/or mycophenolate mofetil
    Stuart, WH
    Court, D
    English, J
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S265 - S265
  • [49] Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis -: Acute response to interferon-β1a treatment and their use as markers of disease activity
    Minagar, A
    Adamashvilli, I
    Jaffe, SL
    Glabus, MF
    Gonzalez-Toledo, E
    Kelley, RE
    AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 111 - 120
  • [50] Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis
    Orefice, Nicola S.
    Alhouayek, Mireille
    Carotenuto, Antonio
    Montella, Silvana
    Barbato, Franscesco
    Comelli, Albert
    Calignano, Antonio
    Muccioli, Giulio G.
    Orefice, Giuseppe
    NEUROTHERAPEUTICS, 2016, 13 (02) : 428 - 438